Brigatinib
Brand: Alunbrig (global)
Anticancer
ALK inhibitor (2nd gen)
Pharmacokinetics
| Half-life | 26 hours |
| Tmax | 2 h |
| Protein Binding | 66 % |
| Volume of Distribution | 1530 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Requires 7-day lead-in 90 mg/day to reduce risk of early pulmonary toxicity. |
⚠️ Safety & Warnings
Severity: Severe
Adverse Effects:
Pneumonitis (early onset), hypertension, visual disturbances, hyperglycemia, myalgia
Contraindications:
Severe pulmonary fibrosis present at baseline
Precautions:
Monitor respiratory symptoms especially during first 7 days; BP & glucose monitoring recommended.
half life ~26 hours → 1.1 days
dose: typical 180 mg/day after 7 day lead-in 90 mg period
(use 180 mg/day)